Renal expression of Toll-like receptor 2 and 4: Dynamics in human allograft injury and comparison to rodents

Molecular Immunology

Volumn 64, Issue 1, 2015, Pages 82-89

  Stribos, Elisabeth G D ^a   Van Werkhoven, Maaike B ^a   Poppelaars, Felix ^a   Van Goor, Harry ^a   Olinga, Peter ^b   Van Son, Willem J ^a   Damman, Jeffrey ^c   Seelen, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Inflammation; Kidney; Toll like receptor 2; Toll like receptor 4; Transplantation

Indexed keywords

TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BIOPSY; COMPARATIVE STUDY; DEMOGRAPHY; FEMALE; FROZEN SECTION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; RAT;

ADULT; ALLOGRAFTS; ANIMALS; ANTIBODY SPECIFICITY; BIOPSY; DEMOGRAPHY; FEMALE; FROZEN SECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MICE; MIDDLE AGED; RATS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84920087124     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.11.003     Document Type: Article

References (31)

1. Batsford S., Duermueller U., Seemayer C., Mueller C., Hopfer H., Mihatsch M. Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease. Nephrol. Dial. Transplant. 2011, 4:1413-1416.
2. Blay J.Y., Rossi J.F., Wijdenes J., Menetrier-Caux C., Schemann S., Negrier S., Philip T., Favrot M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 1997, 3:424-430.
3. de Groot K., Kuklik K., Brocker V., Schwarz A., Gwinner W., Kreipe H., Haller H., Fliser D., Mengel M. Toll-like receptor 2 and renal allograft function. Am. J. Nephrol. 2008, 4:583-588.
4. Dessing M.C., Bemelman F.J., Claessen N., Ten Berge I.J., Florquin S., Leemans J.C. Intragraft Toll-like receptor profiling in acute renal allograft rejection. Nephrol. Dial. Transplant. 2010, 12:4087-4092.
5. Farrar C.A., Keogh B., McCormack W., O'Shaughnessy A., Parker A., Reilly M., Sacks S.H. Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J. 2012, 2:799-807.
6. Goldstein D.R., Tesar B.M., Akira S., Lakkis F.G. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J. Clin. Invest. 2003, 10:1571-1578.
7. Grassmann A., Gioberge S., Moeller S., Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol. Dial. Transplant. 2005, 12:2587-2593.
8. Hoffmann U., Bergler T., Rihm M., Pace C., Kruger B., Jung B., Reinhold S.W., Farkas S., Rummele P., Kramer B.K., Banas B. Impact of Toll-like receptor 2 expression in renal allograft rejection. Nephrol. Dial. Transplant. 2011, 3:1080-1087.
9. Kasiske B.L., Gaston R.S., Gourishankar S., Halloran P.F., Matas A.J., Jeffery J., Rush D. Long-term deterioration of kidney allograft function. Am. J. Transplant. 2005, 6:1405-1414.
10. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 5:373-384.
11. Kruger B., Krick S., Dhillon N., Lerner S.M., Ames S., Bromberg J.S., Lin M., Walsh L., Vella J., Fischereder M., Kramer B.K., Colvin R.B., Heeger P.S., Murphy B.T., Schroppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc. Natl. Acad. Sci. U. S. A. 2009, 9:3390-3395.
12. Leemans J.C., Butter L.M., Pulskens W.P., Teske G.J., Claessen N., van der Poll T., Florquin S. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS ONE 2009, 5:e5704.
13. Lim B.J., Hong S.W., Jeong H.J. Renal tubular expression of Toll-like receptor 4 in cyclosporine nephrotoxicity. APMIS 2009, 8:583-591.
14. Lin M., Yiu W.H., Wu H.J., Chan L.Y., Leung J.C., Au W.S., Chan K.W., Lai K.N., Tang S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 1:86-102.
15. Liu M., Gu M., Xu D., Lv Q., Zhang W., Wu Y. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant. Proc. 2010, 5:1539-1544.
16. McDaniel D.O., Rigney D.A., McDaniel K.Y., Windham W.J., Redmond P., Williams B., Zhou X., Hawxby A., Butt F. Early expression profile of inflammatory markers and kidney allograft status. Transplant. Proc. 2013, 4:1520-1523.
17. Meier-Kriesche H.U., Schold J.D., Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am. J. Transplant. 2004, 8:1289-1295.
18. Naesens M., Li L., Ying L., Sansanwal P., Sigdel T.K., Hsieh S.C., Kambham N., Lerut E., Salvatierra O., Butte A.J., Sarwal M.M. Expression of complement components differs between kidney allografts from living and deceased donors. J. Am. Soc. Nephrol. 2009, 8:1839-1851.
19. Nankivell B.J., Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006, 5:643-654.
20. Nankivell B.J., Kuypers D.R. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011, 9800:1428-1437.
21. Reilly M., Miller R.M., Thomson M.H., Patris V., Ryle P., McLoughlin L., Mutch P., Gilboy P., Miller C., Broekema M., Keogh B., McCormack W., van de Wetering de Rooij J. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clin. Pharmacol. Ther. 2013, 5:593-600.
22. Rossignol D.P., Wasan K.M., Choo E., Yau E., Wong N., Rose J., Moran J., Lynn M. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob. Agents Chemother. 2004, 9:3233-3240.
23. Shah N., Mohamed F.E., Jover-Cobos M., Macnaughtan J., Davies N., Moreau R., Paradis V., Moore K., Mookerjee R., Jalan R. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int. 2013, 3:398-409.
24. Sloane J.A., Blitz D., Margolin Z., Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromol. Med. 2010, 2:149-163.
25. Tsuboi N., Yoshikai Y., Matsuo S., Kikuchi T., Iwami K., Nagai Y., Takeuchi O., Akira S., Matsuguchi T. Roles of toll-like receptors in CC chemokine production by renal tubular epithelial cells. J. Immunol. 2002, 4:2026-2033.
26. Tsukamoto T., Kumamoto Y., Miyao N., Masumori N., Takahashi A., Yanase M. Interleukin-6 in renal cell carcinoma. J. Urol. 1992, 6:1778-1781. (discussion 1781-1782).
27. van Werkhoven M.B., Damman J., Daha M.R., Krikke C., van Goor H., van Son W.J., Hillebrands J.L., van Dijk M.C., Seelen M.A. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney. Mol. Immunol. 2013, 3:237-245.
28. Wolfs T.G., Buurman W.A., van Schadewijk A., de Vries B., Daemen M.A., Hiemstra P.S., van't Veer C. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J. Immunol. 2002, 3:1286-1293.
29. Wong Y.N., Rossignol D., Rose J.R., Kao R., Carter A., Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J. Clin. Pharmacol. 2003, 7:735-742.
30. Wu H., Chen G., Wyburn K.R., Yin J., Bertolino P., Eris J.M., Alexander S.I., Sharland A.F., Chadban S.J. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 2007, 10:2847-2859.
31. Yamamoto M., Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract. 2010, 240365.